CD4 and prostate carcinoma: When those patients with localised or locally advanced prostate cancer (n=57) were examined in univariate analysis, only CD4+ T-lymphocyte count achieved statistical significance (HR 2.88, 95% CI 1.15–7.22, P=0.024).